CN105687740A - Drug for treating chronic lymphocytic thyroiditis - Google Patents
Drug for treating chronic lymphocytic thyroiditis Download PDFInfo
- Publication number
- CN105687740A CN105687740A CN201610139877.8A CN201610139877A CN105687740A CN 105687740 A CN105687740 A CN 105687740A CN 201610139877 A CN201610139877 A CN 201610139877A CN 105687740 A CN105687740 A CN 105687740A
- Authority
- CN
- China
- Prior art keywords
- parts
- effects
- chronic lymphocytic
- lymphocytic thyroiditis
- treating chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000030836 Hashimoto thyroiditis Diseases 0.000 title claims abstract description 27
- 208000001204 Hashimoto Disease Diseases 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title abstract description 9
- 241001250596 Pleione Species 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000009526 Fructus Akebiae Substances 0.000 claims description 9
- 241000218989 Trichosanthes Species 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 8
- 208000026435 phlegm Diseases 0.000 abstract description 8
- 230000008961 swelling Effects 0.000 abstract description 6
- 210000004185 liver Anatomy 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 abstract description 3
- 230000027939 micturition Effects 0.000 abstract description 3
- 210000005036 nerve Anatomy 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 206010007247 Carbuncle Diseases 0.000 abstract description 2
- 208000003251 Pruritus Diseases 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000004087 circulation Effects 0.000 abstract description 2
- 210000000936 intestine Anatomy 0.000 abstract description 2
- 230000007803 itching Effects 0.000 abstract description 2
- 244000045947 parasite Species 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 4
- 230000003467 diminishing effect Effects 0.000 abstract 3
- 241000722953 Akebia Species 0.000 abstract 2
- 240000007185 Albizia julibrissin Species 0.000 abstract 2
- 235000011468 Albizia julibrissin Nutrition 0.000 abstract 2
- 235000006463 Brassica alba Nutrition 0.000 abstract 2
- 244000140786 Brassica hirta Species 0.000 abstract 2
- 235000011371 Brassica hirta Nutrition 0.000 abstract 2
- 241000675108 Citrus tangerina Species 0.000 abstract 2
- 241000264877 Hippospongia communis Species 0.000 abstract 2
- 241001278833 Rosa laevigata Species 0.000 abstract 2
- 235000000661 Rosa laevigata Nutrition 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 108700012359 toxins Proteins 0.000 abstract 2
- 230000001914 calming effect Effects 0.000 abstract 1
- 210000003756 cervix mucus Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
- 206010046901 vaginal discharge Diseases 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 6
- 206010020850 Hyperthyroidism Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010018498 Goitre Diseases 0.000 description 3
- 201000003872 goiter Diseases 0.000 description 3
- 208000003532 hypothyroidism Diseases 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000003228 microsomal effect Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 206010067873 Hashitoxicosis Diseases 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010043757 Thyroid pain Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229960003918 levothyroxine sodium Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a drug for treating chronic lymphocytic thyroiditis. The drug is prepared from raw materials in parts by weight as follows: 10 parts of cherokee rose fruits, 13 parts of silktree albizia bark, 8 parts of honeycombs, 5 parts of pseudobulbus cremastrae seu pleiones, 10 parts of pericarpium trichosanthis, 8 parts of white mustard seeds, 12 parts of akebia fruits and 6 parts of green tangerine peels. The cherokee rose fruits have effects of securing essence, reducing urination, astringing the intestines and checking vaginal discharge; the silktree albizia bark has effects of soothing nerves, relieving depression, activating blood circulation and eliminating carbuncles; the honeycombs have effects of dispelling wind, relieving pain, attacking toxins, diminishing swelling, killing parasites and relieving itching; the pseudobulbus cremastrae seu pleiones has effects of clearing heat, removing toxins, diminishing swelling and removing stasis; the pericarpium trichosanthis has effects of clearing the lung, eliminating phlegm, promoting qi circulation, relieving chest stuffiness and removing stasis; the white mustard seeds have effects of reducing phlegm, expelling fluid retention, removing stasis and diminishing swelling; the akebia fruits have effects of soothing the liver, harmonizing the stomach, promoting blood circulation, arresting pain, softening hardness, removing stasis and inducing urination; the green tangerine peels have effects of soothing the liver, relieving stagnant qi, removing qi stagnation and transforming stagnation. Medicines are combined and have effects of softening hardness, removing stasis, nourishing the heart, calming nerves, tonifying the kidney, securing essence and reducing phlegm. Clinical tests prove that the drug can treat the chronic lymphocytic thyroiditis safely and effectively.
Description
Technical field
The present invention relates to a kind of Chinese medicine, be specifically related to a kind of medicine for treating chronic lymphocytic thyroiditis。
Background technology
Chronic lymphocytic thyroiditis (CLT), also known as autoimmune thyroiditis, is a kind of chronic auto-immune disease being antigen with self parathyroid tissue。Kyushu University Hashimoto first (1912) reports 4 examples on Germany's medical journal, therefore is named as again Hashimoto (bridge is originally) thyroiditis (HT), for thyroid inflammation modal in clinic。Chronic lymphocytic thyroiditis is positive as main clinical characteristics with symmetry thyroid anthorisma, serum thyroglobulin antibody (TGA), thyroid microsomal antibody (TMA)。Sickness rate increases sharply in recent years, has been reported that and thinks close with the sickness rate of hyperthyroidism。Primary disease is child and teenager thyromegaly and the modal reason of acquired hypothyroidism。
Chronic lymphocytic thyroiditis is more common in female middle-aged, is also the common cause of child's sporadic goiter。Onset is slowly hidden, and from the beginning of euthyroidism, hyperthyroidism sometimes can be accompanied to show, and when thyroid is corrupted to a certain degree, hypothyroid symptom occurs in most of patients。
Chronic lymphocytic thyroiditis belongs to the categories such as " gas is thin ", " asthenia " of the traditional Chinese medical science。
The cause of disease
The cause of disease of chronic lymphocytic thyroiditis is unclear。With Familial aggregation phenomenon, the several generations of same family that are everlasting occur, and often merge other autoimmune disease, such as pernicious anemia, diabetes, adrenal insufficiency etc., therefore think that CLT is environmental factors and the coefficient result of inherited genetic factors。The impact of environmental factors mainly includes infecting and iodide excessive in meals。In recent years, more research shows, tumor susceptibility gene plays a role in morbidity。
Clinical manifestation
1. slower development, the course of disease is longer, and early stage can be asymptomatic, when goiter occurs, course of disease average out to 2～4 years。
2. common malaise, many patients do not have bottleneck throat sense of discomfort, and 10%～20% patient has the dull pain of local compression sense or region thyreoidea, have light tenderness once in a while。
3. thyroid mostly is bilateral symmetric property, anthorisma, isthmus and pyramidal lobe and often increases simultaneously, it is possible to Unilateral enlargement。Thyroid tends to vary with disease and is gradually increased, but seldom breathing and dysphagia occurs in compressing cervical region。During palpation, thyroid quality is tough, and smooth surface or fine sand are granular, it is possible in the nodositas that differs in size, and general and surrounding tissue, without being adhered, can move up and down during swallowing movement。
4. the general not enlargement of cervical lymph node, minority case also can accompany cervical lymph node enlargement, but matter is soft。
Drug therapy
1. such as euthyroidism, it is not necessary to special treatment, it is necessary to examining。
2. Hypothyroidism patient should row substitutional treatment with thyroid hormone, select thyroid tablet or levothyrocine, until maintenance dose, the index reaching maintenance dose is that clinical symptoms is improved, and TT3, FT3, TT4, FT4, TSH are normal。
3. the Hashitoxicosis patient course of disease is identical with inflammatory hyperthyroidism, and majority does not need treatment, experience hyperthyroidism phase, first merit normal phase, hypothyroidism phase and four periods of first merit normal phase。Transient hyperthyroidism is to beta-blocker anti symptom treatment。
4. glucocorticoid treatment, primary disease generally do not use hormone therapy to some painful chronic thyroiditis patient's thyroid pain, enlargement obvious time, can add with prednisone, decrement, medication 1～2 month gradually after improvement。
5. treatment by Chinese herbs is started with marrow, whole body therapeutic, makes disease start to take a turn for the better, and human body recovers normal physiological function。
Medical material involved in the present invention is all recorded in " China's book on Chinese herbal medicine " as seen。
Summary of the invention
It is desirable to provide a kind of medicine for treating chronic lymphocytic thyroiditis, by selecting suitable medical material and proportioning thereof, reach safely and effectively to cure the purpose of chronic lymphocytic thyroiditis。
In order to achieve the above object, the present invention is by the following technical solutions:
A kind of medicine for treating chronic lymphocytic thyroiditis, it is characterized in that, it is to be prepared from by the raw medicinal material of following weight proportion: Fructus Rosae Laevigatae 10 parts, Cortex Albiziae 13 parts, Nidus Vespae 8 parts, Pseudobulbus Cremastrae Seu Pleiones 5 parts, the fruit-rind of Chinese trichosanthes 10 parts, Semen Sinapis Albae 8 parts, Fructus Akebiae 12 parts, 6 parts of Pericarpium Citri Reticulatae Viride。
Illustrate the method have the benefit that below in conjunction with theories of Chinese materia medica
It has been recognised by the inventors that the cause of disease of chronic lymphocytic thyroiditis is relevant with long-term disorder of emotion。Pathological change is long-term spirit depressing, and feelings will is lost smooth, liver imbalance and, cause depression of liver-QI, stagnation of QI causing phlegm retention, stop up knot throat。The stagnation of QI with the passing of time, fire-transformation impairment of YIN, then cause yin asthenia generating intrinsic heat。If protracted inflammation is not healed, deficiency of YIN affecting YANG, the card of common deficiency of spleen-YANG and kidneyYANG。Therefore nourishing YIN and clearing away heat, hard masses softening and resolving, warming and recuperating the spleen and kidney, activating QI to eliminate phlegm are then taked in treatment。
The present invention uses: Fructus Rosae Laevigatae controlling nocturnal emission with astringent drugs reducing urination, astringing intestine to stop diarrhea leukorrhagia stopping；Cortex Albiziae is calmed the nerves resolving depression, eliminating carbuncle of invigorating blood circulation；Nidus Vespae wind-expelling pain-stopping, counteracting toxic substances is subsided a swelling, killing parasites for relieving itching；Pseudobulbus Cremastrae Seu Pleiones heat-clearing and toxic substances removing, dispersing swelling and dissipating binds；Fruit-rind of Chinese trichosanthes removing heat from the lung and dissipating phlegm, promoting the circulation of QI the chest stuffiness relieving, eliminating stagnation；Semen Sinapis Albae reduces phlegm by drink, mass dissipating and swelling eliminating；Fructus Akebiae dispersing the stagnated liver-QI for regulating the stomach, promoting blood circulation and stopping pain, hard masses softening and resolving, diuresis；Pericarpium Citri Reticulatae Viride is soothing the liver dispelling the stagnated QI, removing food stagnancyization is stagnant。All medicines share, reach hard masses softening and resolving, nourish heart allay excitement, supplementing the kidney to control the nocturnal, dissipating phlegm and resolving masses effect。
Below in conjunction with clinical laboratory data, beneficial effects of the present invention is described:
1, physical data
Inventor collects 80 example chronic lymphocytic thyroiditis patients altogether between in August ,-2015 in July, 2013。It is randomly divided into: treatment group 40 example, matched group 40 example。Male 5 examples of wherein treatment group, female 35 example, 26～57 years old age, the course of disease 2～8 years；Matched group man 6 examples, female 34 example, between 28～56 years old age, the course of disease 3～8 years。The data such as two groups of sexes, age, courses of disease there was no significant difference, and has comparability。
Diagnostic criteria
1. thyroid anthorisma, tough and tensile, nodosity and air spots；
2. oneself or microsomal antibody of thyroid ball egg is positive, and titration valency is general higher, especially addicted to oxygen degeneration type and fibroplasia type；
3. thyrotropin (TSH) raises；
4. thyroid scintiscan has irregular concentration and sparse；
5. perchlorate discharge test is positive。
1. inclusive criteria meets diagnostic criteria；2. age 18～70 years old；3. compliance is good；4. Informed Consent Form is signed voluntarily。
Exclusion standard 1. gestation, women breast-feeding their children；2. suffer from severe cardiac, lung, liver, renal disease patient；3. spiritedness systemic disease, it is impossible to partner treatment person；4. allergic constitution and those who are allergic to this drug。
2, Therapeutic Method
The capsule that the oral present invention specific embodiment 3 for the treatment of group prepares, every day 3 times。Treat 1 month。
Matched group is administered orally levothyroxine sodium, each 30 μ g, every day 3 times。Treat 1 month。
3, criterion of therapeutical effect and therapeutic outcome
3.1 criterions of therapeutical effect
1. recovery from illness: thyroid morphology and functional rehabilitation are normal, the sings and symptoms of chronic lymphocytic thyroiditis disappears, serum thyroglobulin antibody (TGA), thyroid microsomal antibody (TMA) are turned out cloudy or titre declines > 50%, erythrocyte sedimentation rate is normal；
2. effective: thyroid function remains normal substantially, and diagnosing cervical lump disappears substantially, clinical symptom relief, TGA and TMA titre declines >=20% and≤50%；
3. invalid: clinical symptoms and Testing index are not up to effective standard。
3.2 treatment statistical results are in Table 1。
1 liang of table group comparitive study
Visible, chronic lymphocytic thyroiditis can safely and effectively be treated by the medicine that the present invention prepares, and cure rate is high。
Detailed description of the invention
In order to be more fully understood that and implement the present invention, further illustrate the present invention below in conjunction with specific embodiment。
Embodiment 1
Weigh: Fructus Rosae Laevigatae 10 grams, Cortex Albiziae 13 grams, Nidus Vespae 8 grams, Pseudobulbus Cremastrae Seu Pleiones 5 grams, the fruit-rind of Chinese trichosanthes 10 grams, Semen Sinapis Albae 8 grams, Fructus Akebiae 12 grams, 6 grams of Pericarpium Citri Reticulatae Viride；Add 8 times amount water, decoct 1.5 hours, filter；Filtering residue adds 6 times amount water, decocts 1 hour, filters；Merging filtrate, is concentrated into 120 grams, must meet the decoct of one day consumption of adult normal。
For treating chronic lymphocytic thyroiditis。Oral, daily once。
Embodiment 2
Weigh: Fructus Rosae Laevigatae 10 grams, Cortex Albiziae 13 grams, Nidus Vespae 8 grams, Pseudobulbus Cremastrae Seu Pleiones 5 grams, the fruit-rind of Chinese trichosanthes 10 grams, Semen Sinapis Albae 8 grams, Fructus Akebiae 12 grams, 6 grams of Pericarpium Citri Reticulatae Viride；Add 10 times amount water, decoct 2 hours, filter；Filtering residue adds 8 times amount water, decocts 1.5 hours, filters；Merging filtrate, concentration, dry, packaging, the powder of one day consumption of adult normal must be met。
For treating chronic lymphocytic thyroiditis。Oral, every bu is taken for twice sooner or later。
Embodiment 3
Weigh: Fructus Rosae Laevigatae 10 grams, Cortex Albiziae 13 grams, Nidus Vespae 8 grams, Pseudobulbus Cremastrae Seu Pleiones 5 grams, the fruit-rind of Chinese trichosanthes 10 grams, Semen Sinapis Albae 8 grams, Fructus Akebiae 12 grams, 6 grams of Pericarpium Citri Reticulatae Viride；Add 6 times amount water, decoct 3 times, decoct 1 hour every time, merge decoction liquor, concentration, dry, load capsule shells, the capsule of one day consumption of adult normal must be met。
For treating chronic lymphocytic thyroiditis。Oral, every bu morning, noon and afternoon take for three times。
Claims (4)
1. the medicine being used for treating chronic lymphocytic thyroiditis, it is characterized in that, it is to be prepared from by the raw medicinal material of following weight proportion: Fructus Rosae Laevigatae 10 parts, Cortex Albiziae 13 parts, Nidus Vespae 8 parts, Pseudobulbus Cremastrae Seu Pleiones 5 parts, the fruit-rind of Chinese trichosanthes 10 parts, Semen Sinapis Albae 8 parts, Fructus Akebiae 12 parts, 6 parts of Pericarpium Citri Reticulatae Viride。
2. a kind of medicine for treating chronic lymphocytic thyroiditis as claimed in claim 1, it is characterized in that, its preparation method is: weigh: Fructus Rosae Laevigatae 10 parts, Cortex Albiziae 13 parts, Nidus Vespae 8 parts, Pseudobulbus Cremastrae Seu Pleiones 5 parts, the fruit-rind of Chinese trichosanthes 10 parts, Semen Sinapis Albae 8 parts, Fructus Akebiae 12 parts, 6 parts of Pericarpium Citri Reticulatae Viride；Add 8 times amount water, decoct 1.5 hours, filter；Filtering residue adds 6 times amount water, decocts 1 hour, filters；Merging filtrate, is concentrated into 120 parts, obtains decoct；Above-mentioned part each means weight portion。
3. a kind of medicine for treating chronic lymphocytic thyroiditis as claimed in claim 1, it is characterized in that, its preparation method is: weigh: Fructus Rosae Laevigatae 10 parts, Cortex Albiziae 13 parts, Nidus Vespae 8 parts, Pseudobulbus Cremastrae Seu Pleiones 5 parts, the fruit-rind of Chinese trichosanthes 10 parts, Semen Sinapis Albae 8 parts, Fructus Akebiae 12 parts, 6 parts of Pericarpium Citri Reticulatae Viride；Add 10 times amount water, decoct 2 hours, filter；Filtering residue adds 8 times amount water, decocts 1.5 hours, filters；Merging filtrate, concentration, dry, packaging, obtain powder；Above-mentioned part each means weight portion。
4. a kind of medicine for treating chronic lymphocytic thyroiditis as claimed in claim 1, it is characterized in that, its preparation method is: weigh: Fructus Rosae Laevigatae 10 parts, Cortex Albiziae 13 parts, Nidus Vespae 8 parts, Pseudobulbus Cremastrae Seu Pleiones 5 parts, the fruit-rind of Chinese trichosanthes 10 parts, Semen Sinapis Albae 8 parts, Fructus Akebiae 12 parts, 6 parts of Pericarpium Citri Reticulatae Viride；Add 6 times amount water, decoct 3 times, decoct 1 hour every time, merge decoction liquor, concentration, dry, load capsule shells, obtain capsule；Above-mentioned part each means weight portion。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610139877.8A CN105687740A (en) | 2016-03-11 | 2016-03-11 | Drug for treating chronic lymphocytic thyroiditis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610139877.8A CN105687740A (en) | 2016-03-11 | 2016-03-11 | Drug for treating chronic lymphocytic thyroiditis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105687740A true CN105687740A (en) | 2016-06-22 |
Family
ID=56221345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610139877.8A Withdrawn CN105687740A (en) | 2016-03-11 | 2016-03-11 | Drug for treating chronic lymphocytic thyroiditis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105687740A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451433A (en) * | 2010-10-27 | 2012-05-16 | 魏巍 | Preparation method of traditional Chinese medicine formula for treating thyroid adenoma |
| CN104288514A (en) * | 2014-10-26 | 2015-01-21 | 卞永兴 | Traditional Chinese medicine for treating hyperthyroidism |
-
2016
- 2016-03-11 CN CN201610139877.8A patent/CN105687740A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451433A (en) * | 2010-10-27 | 2012-05-16 | 魏巍 | Preparation method of traditional Chinese medicine formula for treating thyroid adenoma |
| CN104288514A (en) * | 2014-10-26 | 2015-01-21 | 卞永兴 | Traditional Chinese medicine for treating hyperthyroidism |
Non-Patent Citations (1)
| Title |
|---|
| 方邦江，等: "软坚消瘿汤治疗慢性淋巴细胞性甲状腺炎的临床研究", 《中西医结合学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106421633B (en) | A kind of pharmaceutical composition and preparation method thereof for treating Hashimoto's thyroiditis | |
| CN101785823B (en) | Traditional Chinese medicine combination and preparation method for malaise, palpitation and insomnia treatment | |
| CN101693102A (en) | Traditional Chinese medicine compound for treating diseases of incoordination between the spleen and the stomach and abdominal fullness and distention and preparation method thereof | |
| CN101757540A (en) | Traditional Chinese medicine composition for treating nephrotic syndrome and preparation method thereof | |
| CN101683487A (en) | Medicinal composition for treating inappetence, indigestion and apocleisis and preparation method thereof | |
| CN110327437B (en) | Traditional Chinese medicine for treating chronic diarrhea and preparation method thereof | |
| CN109224039B (en) | Chinese medicinal composition for treating kidney fibrosis and tonifying kidney | |
| CN110974925A (en) | Thyroid nodule preparation and preparation method thereof | |
| CN101711852A (en) | Traditional Chinese medicine composition for treating injury symptoms of liver cells and preparation method | |
| CN105687740A (en) | Drug for treating chronic lymphocytic thyroiditis | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN102824469A (en) | Detoxification traditional Chinese medicine and preparation method thereof | |
| CN105770087B (en) | Mongolian medicinal composition for treating diabetes, hyperlipidemia and primary hyperviscosity | |
| CN110946905B (en) | Traditional Chinese medicine composition applied to acupuncture points of peritoneal dialysis patients and preparation method and application thereof | |
| CN107213426A (en) | Treat Chinese patent drug of mammary gland disease and preparation method thereof | |
| CN105796658A (en) | Meidcament for treating female climacteric syndromes | |
| CN100571722C (en) | Treatment is suffered from a deficiency of the kidney and the pharmaceutical composition of climacteric syndrome and preparation method thereof | |
| Patel et al. | A Comprehensive Review on Treatments for Polycystic Ovarian Syndrome (PCOS) | |
| CN105497157A (en) | Medicine used for treating alopecia cicatrisata | |
| Clare | Case Report on a Positive Outcome of Treating Urticaria and Angioedema with Western Herbal Medicine Therapeutic Intervention | |
| CN118045141A (en) | A Chinese medicinal composition for treating diabetes, and its preparation method | |
| CN108939009A (en) | A kind of External-applicationtraditional traditional Chinese medicinal of adjuvant treatment of hyperthyroidism | |
| CN104721253B (en) | The Chinese medicine composition and preparation method thereof for treating chronic lymphocytic thyroiditis | |
| CN102266524B (en) | Traditional Chinese medicine for treating chronic heart failure and preparation method thereof | |
| CN105853753A (en) | Medicine for treating hyperthyroidism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160622 |
|
| WW01 | Invention patent application withdrawn after publication |